Karas Eric — SEC Form 4 filings
SEC reporting owner CIK 1951287. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-12.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-08-21 to 2026-06-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 7 filings — 95,000 shares, $1,305,284 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: sale of 15,000 shares @ $16.99 ($254,860) in ARS Pharmaceuticals, Inc., filed 2025-07-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | Chief Commercial Officer | 9 | — | 8 legs · 95,000 sh · $1,305,284 | 18 |
Form 4 filings — Karas Eric
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-12 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 25,000 @ $1.50 · Sale (S): 25,000 @ $10 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 15,000 @ $1.50 · Sale (S): 15,000 @ $16.99 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 15,000 @ $1.50 · Sale (S): 15,000 @ $16 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 10,000 @ $1.50 · Sale (S): 10,000 @ $14 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Grant/award (A): 152,300 (derivative) @ $0 | EDGAR |
| 2024-12-04 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 3,717 @ $1.50 · Sale (S): 3,717 @ $14.11 · Option exercise (M): 6,283 @ $1.50 · Sale (S): 6,283 @ $14 · Option exercise (M): 3,717 (derivative) @ $0 · Option exercise (M): 6,283 (derivative) @ $0 | EDGAR |
| 2024-09-19 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 10,000 @ $1.50 · Sale (S): 10,000 @ $14 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-08-21 | 4 | ARS Pharmaceuticals, Inc. (SPRY) | Option exercise (M): 10,000 @ $1.50 · Sale (S): 10,000 @ $14 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1951287 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →